Skip to main content
All lobbying filings

Sun Pharmaceutical Industries, Inc.

Sun Pharmaceutical Industries, Inc. filed a Q3 report for Sun Pharmaceutical Industries, Inc. on October 20, 2026.

Lobbying for Sun Pharmaceutical Industries, Inc. · Pharmaceuticals

As filed: SUN PHARMACEUTICAL INDUSTRIES, INC. for SUN PHARMACEUTICAL INDUSTRIES, INC.

All filings by Sun Pharmaceutical Industries, Inc. · Everything Sun Pharmaceutical Industries, Inc. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$140,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
New Jersey

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Health Issues

H.R. 5526 - Biosimilar Red Tape Elimination Act; all provisions. S. 1414 - Expedited Access to Biosimilars Act; all provisions. S. 2658 - Medication Affordability and Patent Integrity Act; all provisions.

Trade (domestic/foreign)

Issues related to Section 232 pharmaceutical tariffs.

 Bills named in this filing 3
  • H.R. 5526
    Biosimilar Red Tape Elimination Act
  • S. 1414
    Expedited Access to Biosimilars Act
  • S. 2658
    Medication Affordability and Patent Integrity Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem